Mobile

Efficacy and safety following use of a novel nicotine replacement therapy. A multicenter, randomized, double blind, placebo-controlled, parallel group, 52-week study in smokers motivated to quit

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-006845-13

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of NMS versus placebo in smokers to achieve continuous abstinence from smoking from the week 2 visit until and including the week 6, week 24, and week 52 visits, respectively.

Critère d'inclusion

  • For the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit abruptly

Liens